Risankizumab: Mechanism of action, clinical and translational science

• Asıl Yazarlar: Yinuo Pang (Yazar), Ronilda D'Cunha (Yazar), Insa Winzenborg (Yazar), Geertruida Veldman (Yazar), Valerie Pivorunas (Yazar), Kori Wallace (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Wiley, 2024-01-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Abstract Risankizumab is a high‐affinity neutralizing anti‐interleukin (IL)‐23 monoclonal antibody marketed in over 40 countries across the globe to treat several inflammatory diseases, such as plaque psoriasis (PsO), psoriatic arthritis (PsA), and Crohn's disease (CD). This paper reviews the r...